Genetic Testing to Understand and Address Renal Disease Disparities


In this genomic medicine implementation pilot project, the investigators aim to conduct a randomized trial in a network of community health centers and primary care facilities to study processes, effects and challenges of incorporating information for apolipoprotein L1 (APOL1)-attributable genetic risk for end stage kidney disease in patients of African ancestry with hypertension .

Study Start Date

November 2014

Estimated Completion Date

April 2017


  • Other: Immediate Genetic Testing


  • Cardiology: Hypertension
  • Nephrology: Chronic Dz/Renal Failure,Hypertension

MeSH Terms

  • Hypertension
  • Immediate Genetic Testing
  • Kidney Diseases
  • Renal Insufficiency

Study ID

Mount Sinai School of Medicine -- GCO 12-1143



Trial ID


Study Type


Trial Phase


Enrollment Quota



Mount Sinai School of Medicine

Inclusion Criteria

  • Ages18-65
  • Self-identifies as Black/African American
  • History of hypertension
  • Patient at a participating site

Exclusion Criteria

  • History of Chronic Kidney Disease
  • History of Diabetes
  • Pregnant
  • Cognitively impaired/unable to provide consent
  • Terminally ill
  • Planning to leave area of study permanently during the one year study period




18 Years to 65 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Study Locations and Contact Information (2)

Study Location Distance Name Phone Email
Icahn School of Medicine at Mount Sinai - New York, New York 46.8 miles None None None
Institute for Family Health - New York, New York 53.3 miles None None None provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.